Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials

Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials

Seokuee Kim,1,2 SeungHwan Lee,1,3 Joo-Youn Cho,1,3 Seo Hyun Yoon,1,3 In-Jin Jang,1,3 Kyung-Sang Yu1,31Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, 2Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 3Department of Cli...

Full description

Bibliographic Details
Main Authors: Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS
Format: Article
Language:English
Published: Dove Medical Press 2017-11-01
Series:Drug Design, Development and Therapy
Subjects:
Pharmacokinetics
Phase 1
First-in-human
NQO1
Pharmacogenomics
Online Access:https://www.dovepress.com/pharmacokinetics-and-tolerability-of-mb12066-a-beta-lapachone-derivati-peer-reviewed-article-DDDT

Similar Items

Similar Items